Iparomlimab represents a highly specialized humanized IgG1 monoclonal antibody specifically engineered to target the human PD-1 receptor with exceptional binding affinity and a slow dissociation rate, effectively facilitating the measurable blockade of the PD-1/PD-L1 inhibitory axis across various preclinical experimental models to evaluate the restoration of T-cell effector functions during strictly monitored laboratory observation periods and molecular investigations to ensure high experimental sensitivity.